Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors.
Innate immunity receptors are germline-encoded receptors that can sense molecular signatures of pathogens and cancer cells. Recent advances in immunology demonstrate the key role of these receptors in inflammation and initiation of subsequent immune responses, including adaptive immunity. Pharmaceutical interest in this field has grown with the retrospective demonstration that some marketed drugs targeting cancer or infectious diseases act via those receptors. In this review, I present an update on the scientific rationale for targeting one class of innate immunity receptor, the Toll-like receptors, and an update on the development status of corresponding drug candidates in infectious diseases, cancer, allergy and vaccines.
Romagne
Francois
F
Innate Pharma, 121 Ancien Chemin de Cassis, 13009 Marseille, France. romagne@innate-pharma.fr
D000818:Animals; D003141:Communicable Diseases / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D015195:Drug Design; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D018448:Models, Immunological; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D011971:Receptors, Immunologic / Q000819:agonists* / Q000276:immunology; D051193:Toll-Like Receptors / Q000819:agonists* / Q000276:immunology
D011971:Receptors, Immunologic; D051193:Toll-Like Receptors